Context Therapeutics: Undervalued Cancer Fighter
Context Therapeutics offers a compelling long opportunity, with three differentiated bispecific T-cell engagers targeting solid tumors and strong early-stage clinical momentum. The company is well-capitalized, with $89 million in cash and access to additional funding, supporting operations through key Phase I data milestones into 2027. CNTX trades at a deep discount to book value and is technically oversold; positive clinical data could trigger a significant re-rating and share price upside.
Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Context Therapeutics Inc. (CNTX), Blue Bird (BLBD), Dycom Industries (DY) and Leidos (LDOS).
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
Here is how Context Therapeutics Inc. (CNTX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
Here is how Context Therapeutics Inc. (CNTX) and Co-Diagnostics, Inc. (CODX) have performed compared to their sector so far this year.
Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline
Context Therapeutics Inc.'s acquisition of CT-95, targeting MSLN expressing solid tumors, brings another shot on goal for its pipeline of T cell engagers. CTIM-76 is another T cell engager in the pipeline; however, it is being developed to go after oncofetal protein CLDN6, which is only highly expressed in embryonic tissue. With both phase 1 studies of CT-95 and CTIM-76 underway soon, it is highly likely that preliminary data from both trials could be released in 2025.
The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains
Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company.
